RESEARCH ACTIVITY MAP

Allergy

22

CLINICAL TRIALS454

PHASESSITES

Undefined
23%

22TRIALS

Phase 336%

Note: Individual sites participating in multiple trials are counted multiple times

Phase 241%RESEARCH ACTIVITY MAP

Cardiology

45

CLINICAL TRIALS931

PHASES

SITES

Phase 213%

Undefined
25%

45
TRIALS

Phase 362%

Note: Individual sites participating in multiple trials are counted multiple times

RESEARCH ACTIVITY MAP

CNS

53

CLINICAL TRIALS

826

PHASES

SITES

Phase 377%

53
TRIALS

Note: Individual sites participating in multiple trials are counted multiple times

Phase 411%
Undefined
2%
Phase 16%
Phase 211%

RESEARCH ACTIVITY MAP

Dermatology

2

CLINICAL TRIALS

8PHASES

SITES

Phase 3100%

2TRIALS

Note: Individual sites participating in multiple trials are counted multiple times

RESEARCH ACTIVITY MAP

Endocrine metabolic disease64

CLINICAL TRIALS877

PHASES

SITES

Phase 367%

Note: Individual sites participating in multiple trials are counted multiple times

64
TRIALS

Phase 43%
Undefined
17%
Phase 15%
Phase 28%

RESEARCH ACTIVITY MAP

Gastroenterology

9CLINICAL TRIALS364

PHASES

SITES

Phase 111%

Undefined56%

Note: Individual sites participating in multiple trials are counted multiple times

9TRIALS

Phase 333%

RESEARCH ACTIVITY MAP

Hematology

29

CLINICAL TRIALS138

PHASES

SITES

Phase 376%

Note: Individual sites participating in multiple trials are counted multiple times

29
TRIALS

Phase 43%
Undefined
7%
Phase 214%RESEARCH ACTIVITY MAP

Immunology

89

CLINICAL TRIALS

4,113

PHASES

SITES

Phase 355%

89

Phase 44%
Undefined12%
Phase 16%

TRIALS

Phase 223%

Note: Individual sites participating in multiple trials are counted multiple times

RESEARCH ACTIVITY MAP

Infectious disease55

CLINICAL TRIALS706

PHASESSITES

Phase 49%
Phase 355%

55

Undefined
15%

TRIALS

Phase 15%
Phase 216%

Note: Individual sites participating in multiple trials are counted multiple times

RESEARCH ACTIVITY MAP

Musculoskeletal disease11

CLINICAL TRIALS

111

PHASES

SITES

Phase 218%

Undefined
18%

11TRIALS

Phase 364%

Note: Individual sites participating in multiple trials are counted multiple times

RESEARCH ACTIVITY MAPOncology

235

CLINICAL TRIALS

1,943

PHASES

SITES

Phase 337%

235

Phase 42%
Undefined
4%TRIALS

Phase 227%

Note: Individual sites participating in multiple trials are counted multiple times

Phase 130%

RESEARCH ACTIVITY MAP

Ophthalmology

8

CLINICAL TRIALS

88

PHASES

SITES

Undefined
25%

Phase 412%

Note: Individual sites participating in multiple trials are counted multiple times

8TRIALS

Phase 363%

RESEARCH ACTIVITY MAP

Rare disease*20

CLINICAL TRIALS

329

PHASES

SITES* Rare disease includes conditions such as:
Gaucher Disease, Myelofibrosis, and Bahcet’s Disease,which could not be categorized into other therapeutic areas

Undefined
20%

20TRIALS

Phase 350%

Note: Individual sites participating in multiple trials are counted multiple times

Phase 110%Phase 220%

RESEARCH ACTIVITY MAP

Respiratory disease20

CLINICAL TRIALS

421

PHASES

SITES

Phase 420%

Undefined
15%

20
TRIALS

Phase 445%

Note: Individual sites participating in multiple trials are counted multiple times

Phase 110%Phase 210%

RESEARCH ACTIVITY MAP

Urology

10

CLINICAL TRIALS241

PHASESSITESUndefined
10%

10TRIALS

Phase 350%

Note: Individual sites participating in multiple trials are counted multiple times

Phase 240%RESEARCH ACTIVITY MAP

Others10

CLINICAL TRIALS

103

PHASES

SITES

Undefined
30%

10TRIALS

Phase 410%

Note: Individual sites participating in multiple trials are counted multiple times

Phase 360%